Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment

Stock Track

05/27

GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.

The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.

Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1196637242"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196637242\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196637242?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196637242","market":"sg","top_or_hot":-1,"title":"Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment","media":"Stock Track","content":"<p>GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.</p><p>The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.</p><p>Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GenScript Bio Soars 5.57% Intraday on ASCO Data Releases and Valuation Sentiment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-27 09:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.</p><p>The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.</p><p>Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1196637242","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196637242","pubTimestamp":1779846865,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.The surge follows news that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"个股追踪|金斯瑞生物盘中大涨5.57%受ASCO数据公布及估值情绪影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GenScript Bio's stock soared 5.57% during intraday trading on Wednesday, driven by positive developments from its associate company and market sentiment around valuation.The surge follows news that Legend Biotech, in which GenScript holds a significant stake, will present multiple research results at the upcoming ASCO Annual Meeting. This includes Phase 1 preliminary data for LB2102, an investigational DLL3-targeting CAR-T therapy targeting relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, along with new CARVYKTI data disclosures.Market analysts note that the expansion of CAR-T therapy into solid tumor indications represents significant growth potential for GenScript. Additionally, discussions about GenScript's valuation inversion—where its total market capitalization remains below the value of its stake in Legend Biotech—have supported short-term sentiment recovery, contributing to the stock's rebound.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}